Stephen Sheldon - PaxMedica, Common Chief Officer
| PXMDDelisted Stock | USD 0.86 0.18 17.31% |
Insider
Stephen Sheldon is Chief Officer of PaxMedica, Common Stock
| Age | 44 |
| Phone | 914 987 2876 |
| Web | https://www.paxmedica.com |
Stephen Sheldon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephen Sheldon against PaxMedica, Common pink sheet is an integral part of due diligence when investing in PaxMedica, Common. Stephen Sheldon insider activity provides valuable insight into whether PaxMedica, Common is net buyers or sellers over its current business cycle. Note, PaxMedica, Common insiders must abide by specific rules, including filing SEC forms every time they buy or sell PaxMedica, Common'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephen Sheldon over six months ago Disposition of 243 shares by Stephen Sheldon of PaxMedica Common at 0.659 subject to Rule 16b-3 | ||
Stephen Sheldon over a year ago Payment of 971 shares by Stephen Sheldon of PaxMedica Common subject to Rule 16b-3 |
PaxMedica, Common Management Efficiency
The company has return on total asset (ROA) of (2.5596) % which means that it has lost $2.5596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.4696) %, meaning that it created substantial loss on money invested by shareholders. PaxMedica, Common's management efficiency ratios could be used to measure how well PaxMedica, Common manages its routine affairs as well as how well it operates its assets and liabilities.PaxMedica, Common Stock currently holds 173.54 K in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Debt can assist PaxMedica, Common until it has trouble settling it off, either with new capital or with free cash flow. So, PaxMedica, Common's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PaxMedica, Common Stock sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PaxMedica, to invest in growth at high rates of return. When we think about PaxMedica, Common's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| James Foster | Virax Biolabs Group | 39 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Joan Brown | Allarity Therapeutics | 70 | |
| Robert McRae | Palisade Bio | N/A | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| Gabriel BA | Immix Biopharma | 37 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Nandan BS | Immix Biopharma | 62 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| MBA MD | Immix Biopharma | 49 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Chester III | Revelation Biosciences | 44 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
Management Performance
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 |
PaxMedica, Common Stock Leadership Team
Elected by the shareholders, the PaxMedica, Common's board of directors comprises two types of representatives: PaxMedica, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PaxMedica,. The board's role is to monitor PaxMedica, Common's management team and ensure that shareholders' interests are well served. PaxMedica, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PaxMedica, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Howard Weisman, CEO Director | ||
| MS MBA, Ex Chairman | ||
| Zachary Rome, COO Director | ||
| Stephen Sheldon, Chief Officer | ||
| David MD, Chief Officer |
PaxMedica, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PaxMedica, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 | ||||
| Current Valuation | 388.33 K | ||||
| Shares Outstanding | 7.47 M | ||||
| Shares Owned By Insiders | 8.14 % | ||||
| Shares Owned By Institutions | 1.60 % | ||||
| Number Of Shares Shorted | 637.72 K | ||||
| Price To Earning | 1.90 X | ||||
| Price To Book | 1.83 X | ||||
| EBITDA | (16.15 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in PaxMedica, Pink Sheet
If you are still planning to invest in PaxMedica, Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PaxMedica, Common's history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |